Category Archives: Disease

Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

The News: Eureka Therapeutics Inc., a closely held biotechnology company, said that liver cancer patients getting its CAR-T therapy responded to the treatment, one of the first times the immune-system… Read more »

Researchers say autobiographical memory test may foretell Alzheimer’s risk. Study invokes friends, relatives and sparks uneasy self-reflection.

The News: Testing how well people remember past events in their lives could help medical professionals make early predictions about who is at risk for developing Alzheimer’s disease (AD), according… Read more »

Weekly Medical Stock Spotlight: 3 big winners and 2 total duds.

1) ProQR Therapeutics NV (Nasdaq:PRQR) led advancing issues on the Labor Day-shortened week, soaring 107% over the week to $15.80 on Friday (August 31, 2018). The upward move came after the… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

India’s huge pharma/consumer health market in crosshairs of world’s biggest drugmakers. China, Japan, Korea lurking as Asia joins fray with West.

The News: GlaxoSmithKline PLC‘s (London) Indian consumer health unit is drawing the attention of more big-name suitors as the magnitude of the potential there is coming into clearer focus. After… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Forget about Biogen/Eisai’s promising new drug for Alzheimer’s; Study says aggressive blood-pressure treatment with existing meds reduces dementia/AD risk.

The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »